CODX — Co-Diagnostics, Inc.
Is CODX overbought or oversold? Here is the current MarketMoodz read.
Co-Diagnostics, Inc. (CODX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $0.22. The rating moved from Strong Oversold to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.22
- Last changeMoved from Strong Oversold to Oversold on November 13, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Co-Diagnostics, Inc. (CODX) displays a weak financial profile, limited visible revenue growth drivers and high dilution vulnerability typical of small diagnostics companies. Industry flows and investor preference have skewed toward large-cap, defensive healthcare names, reducing near-term appetite for micro-cap diagnostics. Absence of clear upcoming commercial or regulatory catalysts, combined with potential for additional dilutive financings, creates a downside-biased near-term outlook; limited liquidity and penny-stock volatility amplify execution and market risks.
Key factors
- Thin financial position with history of operating losses and likely limited cash runway
- High dilution risk from past/suspected convertible-debt and equity financings
- Concentrated product mix and reliance on cyclical diagnostic test demand
- Small-cap, low-liquidity profile increases volatility and trading risk
- Sector flows are favoring large-cap pharma and defensive healthcare rather than small diagnostics
- Limited recent public disclosure or visible near-term commercial catalysts
- Competitive pressure from larger diagnostics and molecular testing providers
Risks
- Further equity or convertible financings that materially dilute existing shareholders
- Regulatory setbacks, failed validations or adverse FDA/CLIA outcomes
- Commercial adoption or reimbursement delays for existing tests
- Continued negative operating cash flow forcing distressed financing terms
- Sector-wide risk-off episodes that disproportionately impact penny stocks
- Adverse litigation or intellectual-property disputes
- Sharp short-term price moves due to low float and limited liquidity
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CODX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.